Eiyad Alchureiqi, MD
Family Medicine · Lexington, KYNPI 1699728493
Payments from drug & device makers
Across 172 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$483
- Novo Nordisk$406
- Lilly USA, LLC$294
- Corium, LLC$187
- AbbVie$170
- Takeda Pharmaceuticals U.S.A., Inc.$170
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,849100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $483 |
| Novo Nordisk | 21 | $406 |
| Lilly USA, LLC | 17 | $294 |
| Corium, LLC | 13 | $187 |
| AbbVie(2 entities) | 12 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $170 |
| Shield Therapeutics Inc | 1 | $121 |
| GSK | 7 | $112 |
| Exact Sciences | 6 | $88 |
| Biohaven Pharmaceuticals, Inc. | 5 | $75 |
| Merck | 5 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Novartis | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 4 | $50 |
| Genentech USA, Inc. | 4 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| AstraZeneca | 1 | $33 |
| Johnson & Johnson | 2 | $31 |
| Abbott | 2 | $29 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Alkermes, Inc. | 1 | $22 |
| Agile Therapeutics, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Cranial Technologies, Inc | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Neos Therapeutics, LP | 1 | $13 |
| Biogen | 1 | $12 |
| Phadia US Inc. | 1 | $11 |
| Tris Pharma Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,849 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $77,406 |
| JardianceEmpagliflozin | 69 | $62,610 |
| EliquisApixaban | 69 | $53,694 |
| MounjaroTirzepatide | 29 | $30,051 |
| TrulicityDulaglutide | 31 | $29,351 |
| JanuviaSitagliptin Phosphate | 21 | $22,986 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 87 | $19,567 |
| LinzessLinaclotide | 14 | $8,239 |
| MyrbetriqMirabegron | 15 | $6,642 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,635 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $5,474 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 16 | $4,955 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 61 | $4,263 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $4,057 |
| SynthroidLevothyroxine Sodium | 34 | $2,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $406 | $77,40678 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $15 | $69,24582 claims |
| Lilly USA, LLCMounjaro, Trulicity | $294 | $59,40260 claims |
| PfizerEliquis | $483 | $53,69469 claims |
| GSKShingrix, Arexvy | $112 | $24,521103 claims |
| MerckJanuvia | $66 | $22,98621 claims |
| AbbVieLinzess, Synthroid | $170 | $10,65748 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $6,64215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Lexington
- Barbara Fleming-PhillipsLexington$1.4M
- John RichardLexington$226K
- Eleida Tur OlivaLexington$113K
- Susan NeilLexington$18K
- Brian SmithVersailles$7.7M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.